pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·Sep 21·1 min read
save

FDA to replace animal testing terms with broader nonclinical language in regulations

Sep 21, 2026·read at raps ↗RegulatoryNeutral

The U.S. Food and Drug Administration announced it will revise its regulations to replace references to animal testing with broader terms such as "nonclinical tests" and "nonclinical studies".

The change is intended to make the regulatory language more flexible and to support the growing use of alternative, non-animal methods in drug development.

By updating the terminology, the agency hopes to streamline the review process for products that rely on modern testing approaches while still ensuring safety and efficacy standards.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “FDA to remove ‘animal testing’ terminology from its regulations”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoFDA finalizes cell and gene therapy potency guidanceraps
  • 1d agoMifepristone study highlights need for more transparency, data collection in FDA’s REMS programraps
  • 1d agoRecon: FDA approves generic lenacapavir intended for lower income countries; EMA to review Lundbeck's Deanxit for reported serio...raps
  • 1d agoAsia-Pacific Roundup: Australia’s TGA seeks feedback on sharing clinical trial information, ICH GCP proposalsraps
  • 4d agoThis Week at FDA: New ConOps for drug inspections, AI policy proposal, and moreraps